ID   T235
AC   CVCL_6478
SY   ATC235
DR   cancercelllines; CVCL_6478
DR   Cosmic; 1239957
DR   Cosmic; 2054078
DR   Cosmic; 2186781
DR   Wikidata; Q54971452
RX   PubMed=17406368;
RX   PubMed=18713817;
RX   PubMed=23833040;
RX   PubMed=30737244;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=18713817; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,14
ST   D16S539: 11,12
ST   D18S51: 13,19
ST   D21S11: 29
ST   D3S1358: 14
ST   D5S818: 9,12
ST   D7S820: 8,10
ST   D8S1179: 11,14
ST   FGA: 21,23
ST   TH01: 6
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 22
//
RX   PubMed=17406368; DOI=10.1038/sj.bjc.6603578; PMCID=PMC2360140;
RA   Rodrigues R.F., Roque L., Krug T., Leite V.;
RT   "Poorly differentiated and anaplastic thyroid carcinomas: chromosomal
RT   and oligo-array profile of five new cell lines.";
RL   Br. J. Cancer 96:1237-1245(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//